Skip to main content
SpringerLink
Log in

Graves’ Disease in Childhood

  • Chapter
Graves' Disease

  • 2239 Accesses

Abstract

The most prevalent cause of thyrotoxicosis in children is Graves’ disease (GD), and remission occurs only in a modest proportion of patients. Thus most pediatric patients with GD will need treatment with radioactive iodine (RAI; 131I) or surgical thyroidectomy. When antithyroid drugs (ATDs) are prescribed, only methimazole (MMI) should be administered, as PTU is associated with an unacceptable risk of severe liver injury. If remission does not occur following ATD therapy, 131I or surgery should be contemplated. When 131I is administered, dosages should be greater than 150 μCi/g of thyroid tissue, with higher dosages needed for large glands. Considering that there will be low-level whole body radiation exposure associated with 131I, this treatment should be avoided in young children. When surgery is performed, near total or total thyroidectomy is the recommended procedure. Complications for thyroidectomy in children are considerably higher than in adults; thus an experienced thyroid surgeon is needed when children are operated on. Most importantly, the care of children with GD can be complicated and requires physicians with expertise in the area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wilkins L. The diagnosis and treatment of endocrine disorders in children and adolescence. Springfield: Charles Thomas; 1965. p. 141–50.

    Google Scholar 

  2. Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol. 2008;158(6):823–7.

    CAS  PubMed  Google Scholar 

  3. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43.

    CAS  PubMed  Google Scholar 

  4. Conference Proceeding: Hepatic toxicity following treatment for pediatric Graves’ disease meeting: October 28, 2008. Eunice Kennedy Shriver National Institute of Child Health and Human Development. http://bpca.nichd.nih.gov/outreach/index.cfm. 2009 [January 14, 2009]; Available from: http://bpca.nichd.nih.gov/outreach/index.cfm.

  5. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid. 2007;17(11):1103–7.

    CAS  PubMed  Google Scholar 

  6. Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83(11):3767–76.

    CAS  PubMed  Google Scholar 

  7. Fisher DA. Graves’ disease in children. Curr Ther Endocrinol Metab. 1994;5:71–4.

    CAS  PubMed  Google Scholar 

  8. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin N Am. 1998;27(1):109–26.

    CAS  Google Scholar 

  9. LeFranchi S, Mandel SH. Graves’ disease in the neonatal period and childhood. In: Braverman LE, Utiger RD, editors. Clinical text. Philadelphia: JB Lippincott; 1995. p. 1237–46.

    Google Scholar 

  10. Weetman AP. Grave’s disease 1835–2002. Horm Res. 2003;59 Suppl 1:114–8.

    CAS  PubMed  Google Scholar 

  11. Weetman AP. Graves’ disease. N Engl J Med. 2000;343(17):1236–48.

    CAS  PubMed  Google Scholar 

  12. Chapman EM. History of the discovery and early use of radioactive iodine. JAMA. 1983;250(15):2042–4.

    CAS  PubMed  Google Scholar 

  13. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–17.

    CAS  PubMed  Google Scholar 

  14. Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves’ disease: outcome and treatment. J Pediatr Endocrinol Metab. 2003;16(9):1249–55.

    PubMed  Google Scholar 

  15. Talbot NB, Sobel EH, McArthur JW, Crawford JD. Functional endocrinology: from birth to adolescence. Cambridge: Harvard University Press; 1952. p. 1–51.

    Google Scholar 

  16. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves’ disease. Endocrinol Metab Clin N Am. 1998;27(1):225–47.

    CAS  Google Scholar 

  17. Cooper DS. Which Anti-thyroid drug? Am J Med. 1986;80:1165–8.

    CAS  PubMed  Google Scholar 

  18. Rivkees SA. 63 Years and 715 days to the “Boxed Warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol. 2010; 2010, 3 pages. Article ID 658267. doi:10.1155/2010/658267.

  19. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360(15):1574–5. Epub 2009/04/10.

    CAS  PubMed  Google Scholar 

  20. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol. 2009;2009:132041. Epub 2009/12/01.

    PubMed Central  PubMed  Google Scholar 

  21. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–23.

    PubMed  Google Scholar 

  22. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2157–62.

    CAS  PubMed  Google Scholar 

  23. Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995;88(9):973–6.

    CAS  PubMed  Google Scholar 

  24. Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, et al. Treatment for childhood-onset Graves’ disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid. 2007;17(1):67–72.

    PubMed  Google Scholar 

  25. Cassio A, Corrias A, Gualandi S, Tato L, Cesaretti G, Volta C, et al. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol. 2006;64(1):53–7.

    CAS  Google Scholar 

  26. Dotsch J, Rascher W, Dorr HG. Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs. 2003;5(2):95–102.

    PubMed  Google Scholar 

  27. Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, et al. Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatr Endocrinol. 2000;13(7):879–85.

    CAS  Google Scholar 

  28. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, et al. Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years. J Pediatr Endocrinol Metab. 1999;12(4):537–41.

    CAS  PubMed  Google Scholar 

  29. Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, et al. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994;131(5):467–73.

    CAS  PubMed  Google Scholar 

  30. Slyper AH, Wyatt D, Boudreau C. Effective methimazole dose for childhood Grave’s disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. 2005;18(6):597–602.

    CAS  PubMed  Google Scholar 

  31. Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2005;2, CD003420.

    PubMed  Google Scholar 

  32. Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves’ disease. Eur J Endocrinol. 2006;154(6):783–6.

    CAS  PubMed  Google Scholar 

  33. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983;98(1):26–9.

    CAS  PubMed  Google Scholar 

  34. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8(3):222–4.

    PubMed  Google Scholar 

  35. Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves’ disease in children. Int J Pediatr Endocrinol. 2010;2010:176970. Epub 2010/03/13.

    PubMed Central  PubMed  Google Scholar 

  36. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid. 2005;15(3):292–7.

    CAS  PubMed  Google Scholar 

  37. Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, et al. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves’ disease. Clin Endocrinol. 2004;60(6):671–5.

    CAS  Google Scholar 

  38. Guma M, Olive A, Juan M, Salinas I. ANCA antibodies in Graves’ disease. Ann Rheum Dis. 2002;61(1):90–1.

    PubMed Central  CAS  PubMed  Google Scholar 

  39. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005;38(1):93–103.

    CAS  PubMed  Google Scholar 

  40. Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves’ disease. J Med Assoc Thai. 2002;85 Suppl 4:S1295–301.

    PubMed  Google Scholar 

  41. Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, Tsuchiya M, et al. Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves’ disease treated with propylthiouracil. Clin Nephrol. 2005;63(6):437–45.

    CAS  PubMed  Google Scholar 

  42. Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol. 1998;10(1):45–50.

    CAS  PubMed  Google Scholar 

  43. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985;60(5):1019–24.

    CAS  PubMed  Google Scholar 

  44. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997;82(6):1719–26.

    CAS  PubMed  Google Scholar 

  45. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics. 2008;121(3):e481–8.

    PubMed  Google Scholar 

  46. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93(10):3817–26.

    CAS  PubMed  Google Scholar 

  47. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab. 2012;97(1):110–9. Epub 2011/10/28.

    CAS  PubMed  Google Scholar 

  48. Weetman AP. Graves’ hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab. 2006;2:2–3.

    PubMed  Google Scholar 

  49. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, et al. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990;70(3):675–9.

    CAS  PubMed  Google Scholar 

  50. Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A. Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Investig. 1992;15(11):815–20.

    CAS  Google Scholar 

  51. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves’ disease–prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50(1):127–32.

    CAS  Google Scholar 

  52. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997;7(5):755–60.

    CAS  PubMed  Google Scholar 

  53. Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves’ disease. Cochrane Database Syst Rev. 2008;3, CD006294.

    PubMed  Google Scholar 

  54. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987;64(6):1241–5.

    CAS  PubMed  Google Scholar 

  55. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000;85(10):3678–82.

    CAS  PubMed  Google Scholar 

  56. Vitti P, Rago T, Chiovato L, Pallini S, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:69–375.

    Google Scholar 

  57. Kim WB, Chung HK, Lee HK, Kohn LD, Tahara K, Cho BY. Changes in epitopes for thyroid-stimulating antibodies in Graves’ disease sera during treatment of hyperthyroidism: therapeutic implications. J Clin Endocrinol Metab. 1997;82:1953–9.

    CAS  PubMed  Google Scholar 

  58. Davies T, Roti E, Braverman LE, De Groot LJ. Thyroid controversy–stimulating antibodies. J Clin Endocrinol Metab. 1998;83:3777–85.

    CAS  PubMed  Google Scholar 

  59. Rapoport B, Greenspan FS, Filetti P. Pepitone. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. J Clin Endocrinol Metab. 1984;58:332–8.

    CAS  PubMed  Google Scholar 

  60. Wilson R, McKilop JH, Henderson N, Pearson DW, Thomson JA. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves’ disease. Clin Endocrinol. 1986;25:151–6.

    CAS  Google Scholar 

  61. Bouma DJ, Kammer H, Greer MA. Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. J Clin Endocrinol Metab. 1982;55:1138–42.

    CAS  PubMed  Google Scholar 

  62. Greer MA, Kammer H, Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N Engl J Med. 1977;297:173–6.

    CAS  PubMed  Google Scholar 

  63. Bing RF. Early remission in thyrotoxicosis produced by short coursed of treatment. Acta Endocrinol Suppl (Copenh). 1982;100:221–3.

    CAS  Google Scholar 

  64. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715–25. Epub 2002/11/06.

    CAS  PubMed  Google Scholar 

  65. Wintergerst KA, Rogers ES, Foster MB. Hyperthyroidism presenting with hyperglycemia in an adolescent female. J Pediatr Endocrinol Metab. 2011;24(5–6):385–7. Epub 2011/08/10.

    PubMed  Google Scholar 

  66. Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, et al. Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes. 2012;13(8):652–5. Epub 2012/07/05.

    PubMed  Google Scholar 

  67. Benavides VC, Rivkees SA. Myopathy associated with acute hypothyroidism following radioiodine therapy for Graves disease in an adolescent. Int J Pediatr Endocrinol. 2010;2010. Epub 2010/09/28.

    Google Scholar 

  68. van Veenendaal NR, Rivkees SA. Treatment of pediatric Graves’ disease is associated with excessive weight gain. J Clin Endocrinol Metab. 2011;96(10):3257–63. Epub 2011/08/19.

    PubMed Central  PubMed  Google Scholar 

  69. Williams ED. Biological effects of radiation on the thyroid. In: Braverman LE, Utiger RD, editors. The thyroid. Philadelphia: J.B. Lippincott Co.; 1986. p. 421–36.

    Google Scholar 

  70. Hertz BE, Schuller KE. Saul Hertz, MD (1905–1950): a pioneer in the use of radioactive iodine. Endocr Pract. 2010;16(4):713–5.

    PubMed  Google Scholar 

  71. Sheline GE, McCormack KR, Galante M. Thyroid nodules occurring late after treatment of thyrotoxicosis with radioiodine. J Clin Endocrinol Metab. 1962;22:8–17.

    CAS  PubMed  Google Scholar 

  72. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab. 1974;38:976–98.

    CAS  PubMed  Google Scholar 

  73. Goolden AWG, Davey JB. The ablation of normal thyroid tissue with iodine-131. Br J Radiol. 1963;36:340–5.

    CAS  PubMed  Google Scholar 

  74. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–41.

    CAS  PubMed  Google Scholar 

  75. Levy WM, Schumacher OP, Gupta M. Treatment of childhood Graves’ disease. A review with emphasis on radioiodine treatment. Cleveland Clin J Med. 1988;55:373–82.

    CAS  Google Scholar 

  76. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves’ hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997;7(2):247–51.

    CAS  PubMed  Google Scholar 

  77. Graham GD, Burman KD. Radioiodine treatment of Graves’ disease. An assessment of its potential risks. Ann Intern Med. 1986;105:900–5.

    CAS  PubMed  Google Scholar 

  78. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Investig. 1995;25(3):186–93.

    CAS  Google Scholar 

  79. Becker DV, Hurly JR. Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med. 1971;1:442–60.

    CAS  PubMed  Google Scholar 

  80. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001;86(5):1865–7.

    CAS  PubMed  Google Scholar 

  81. Refetoff S, Demeester-Mirkine N, Ermans AM, DeGroot LJ. Rapid control of thyrotoxicosis with combined 131I, antithyroid drugs and KI therapy. J Nucl Med Allied Sci. 1977;21:23–9.

    CAS  PubMed  Google Scholar 

  82. Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1983;57:250–3.

    CAS  PubMed  Google Scholar 

  83. Rappaport R, Caplan R, De Groot LJ. Low-dose sodium iodine I 131 therapy in Graves disease. JAMA. 1973;224:1610–3.

    Google Scholar 

  84. Sridama V, DeGroot LJ. Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med. 1989;87:70–3.

    CAS  PubMed  Google Scholar 

  85. Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol. 1986;24:217–22.

    CAS  Google Scholar 

  86. McCullagh EP, Jelden GL, Rodriguez-Antunez A. Incidence of hypothyroidism following small doses of 131I in the treatment of Graves’ disease. Oh State Med J. 1976;72:538–40.

    CAS  Google Scholar 

  87. Dobyns BM. Radiation effects on the thyroid. Effects vary with dosage and sensitivity of the gland to radiation. RI Med J. 1975;58:94–7.

    CAS  Google Scholar 

  88. Safa AM. Treatment of hyperthyroidism with a large initial dose of sodium iodine I 131. Arch Intern Med. 1975;135:673–5.

    CAS  PubMed  Google Scholar 

  89. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40–6.

    CAS  PubMed  Google Scholar 

  90. Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volumes in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab. 1996;81:3257–60.

    CAS  PubMed  Google Scholar 

  91. Hancock LD, Tuttle RM, LeMar H, Baumen J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves’ disease. Clin Endocrinol. 1997;47:425–30.

    CAS  Google Scholar 

  92. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611–7.

    CAS  PubMed  Google Scholar 

  93. Crile G, Schumacher OP. Radioactive iodine treatment of Graves’ disease. Results in 32 children under 16 years of age. Am J Dis Child. 1965;110:501–4.

    PubMed  Google Scholar 

  94. Hayek A, Chapman EM, Crawford JD. Long term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1970;283:949–53.

    CAS  PubMed  Google Scholar 

  95. Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med. 1979;20:847–50.

    CAS  PubMed  Google Scholar 

  96. Starr P, Jaffe HL, Oettinger L. Late results of 131I treatment of hyperthyroidism in 73 children and adolescents. J Nucl Med. 1964;5:81–9.

    CAS  PubMed  Google Scholar 

  97. Starr P, Jaffe HL, Oettinger L. Later results of 131-I treatment of hyperthyroidism in 73 children and adolescence: 1967 follow-up. J Nucl Med. 1969;10:586–90.

    CAS  PubMed  Google Scholar 

  98. Kogut MD, Kaplan SA, Collipp PJ, Tiamsic T, Boyle D. Treatment of hyperthyroidism in children: analysis of forty-five patients. N Engl J Med. 1965;272:217–22.

    CAS  PubMed  Google Scholar 

  99. Moll GW, Patel BR. Pediatric Graves’ disease: therapeutic options and experience with radioiodine at the University of Mississippi Medical Center. South Med J. 1997;90:1017–22.

    PubMed  Google Scholar 

  100. Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1975;292:167–71.

    CAS  PubMed  Google Scholar 

  101. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111(4 Pt 1):745–9.

    PubMed  Google Scholar 

  102. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves’ disease in children. J Pediatr. 2002;141(1):99–103.

    PubMed  Google Scholar 

  103. Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves’ hyperthyroidism? J Clin Endocrinol Metab. 2003;88(3):975–7.

    CAS  PubMed  Google Scholar 

  104. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978–83.

    CAS  PubMed  Google Scholar 

  105. De Groot LJ, Gorman CA, Pinchera A, Bartalena L, Marcocci C, Wiersinga WM, et al. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1995;80:339–40.

    Google Scholar 

  106. Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid. 1997;7(2):241–5.

    CAS  PubMed  Google Scholar 

  107. Saxena KM, Crawford JD, Talbot NB. Childhood thyrotoxicosis: a long term perspective. Br Med J. 1964;2:1153–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  108. Lafranchi S. Thyroiditis and acquired hypothyroidism. Pediatr Ann. 1992;21(1):29. 32–9.

    CAS  PubMed  Google Scholar 

  109. Barnes HV, Blizzard RM. Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolescence. J Pediatr. 1977;91:313–20.

    CAS  PubMed  Google Scholar 

  110. Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery. 1996;120(6):1020–4. discussion 4–5.

    CAS  PubMed  Google Scholar 

  111. Wiersinga WM, Prummel MF. Graves’ ophthalmopathy: a rational approach to treatment. Trends in Endocrinology & Metabolism. 2002;13(7):280–7.

    CAS  Google Scholar 

  112. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med. 1976;17:460–4.

    CAS  PubMed  Google Scholar 

  113. Boice Jr JD. Radiation-induced thyroid cancer–what’s new? J Natl Cancer Inst. 2005;97(10):703–5.

    PubMed  Google Scholar 

  114. Boice Jr JD. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006;295(9):1060–2.

    CAS  PubMed  Google Scholar 

  115. Ron E, Lubin J, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259–77.

    CAS  PubMed  Google Scholar 

  116. Dolphin GW. The risk of thyroid cancers following irradiation. Health Phys. 1968;15:219–28.

    CAS  PubMed  Google Scholar 

  117. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365(9476):2014–23.

    PubMed  Google Scholar 

  118. Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006;91(6):2159–64.

    CAS  PubMed  Google Scholar 

  119. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712–8.

    CAS  PubMed  Google Scholar 

  120. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294(1):71–80.

    CAS  PubMed  Google Scholar 

  121. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res. 1990;50:2283–9.

    CAS  PubMed  Google Scholar 

  122. Holm LE, Hall P, Wiklund K, Lundell G, Berq G, Cederquist E, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991;83:1072–7.

    CAS  PubMed  Google Scholar 

  123. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92(6):2190–6.

    CAS  PubMed  Google Scholar 

  124. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347–55.

    CAS  PubMed  Google Scholar 

  125. Read Jr CH, Tansey MJ, Menda Y. A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89(9):4229–33.

    CAS  PubMed  Google Scholar 

  126. Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics. 2000;20(2):533–46.

    CAS  PubMed  Google Scholar 

  127. Toohey RE, Stabin MG, editors. Comparative analysis of dosimetry parameters for nuclear medicine. ORISE Report 99-1064, 1999. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium; 1996; Gatlinburg, TN.

    Google Scholar 

  128. Health risks from exposure to low levels of ionizing radiation: BEIR VII – Phase 2. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation NRC, editor. Washington, DC: National Academies Press; 2006.

    Google Scholar 

  129. http://nobelprize.org/medicine/laureates/1909/index.html

  130. Ching T, Warden MJ, Fefferman RA. Thyroid surgery in children and teenagers. Arch Otolaryngol. 1977;103:544–6.

    CAS  PubMed  Google Scholar 

  131. Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD. Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child. 1981;135(2):112–7.

    CAS  PubMed  Google Scholar 

  132. Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA. Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol. 1996;134:710–5.

    CAS  PubMed  Google Scholar 

  133. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Investig. 1996;26(1):59–63.

    CAS  Google Scholar 

  134. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93(8):3058–65.

    CAS  PubMed  Google Scholar 

  135. Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R. Effect of patient age on surgical outcomes for Graves’ disease: a case-control study of 100 consecutive patients at a high volume thyroid surgical center. Int J Pediatr Endocrinol. 2013;2013(1):1. Epub 2013/01/29.

    PubMed Central  PubMed  Google Scholar 

  136. Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15(6):569–74.

    PubMed  Google Scholar 

  137. Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin N Am. 2004;84(3):849–74.

    PubMed  Google Scholar 

  138. Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, Neubauer M, et al. Surgery for Graves’ disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg. 2000;24(11):1303–11.

    CAS  PubMed  Google Scholar 

  139. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320–30.

    PubMed Central  CAS  PubMed  Google Scholar 

  140. Breuer C, Tuggle C, Solomon D, Sosa JA. Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children? J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1:79–85. Epub 2012/11/15.

    PubMed Central  PubMed  Google Scholar 

  141. Peroni E, Angiolini MR, Vigone MC, Mari G, Chiumello G, Beretta E, et al. Surgical management of pediatric Graves’ disease: an effective definitive treatment. Pediatr Surg Int. 2012;28(6):609–14. Epub 2012/05/01.

    PubMed  Google Scholar 

  142. Read Jr CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89(9):4229–33.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

The authors have no potential conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Florida Shands Children’s Hospital, University of Florida College of Medicine, Pediatrics – Chairman’s Office, 1600 SW Archer Road – Room R1-118, 32610-0296, Gainesville, FL, USA

    Scott A. Rivkees M.D.

Authors
  1. Scott A. Rivkees M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott A. Rivkees M.D. .

Editor information

Editors and Affiliations

  1. Mayo Clinic College of Medicine, Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, USA

    Rebecca S. Bahn

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rivkees, S.A. (2015). Graves’ Disease in Childhood. In: Bahn, R. (eds) Graves' Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2534-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2534-6_11

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2533-9

  • Online ISBN: 978-1-4939-2534-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation